CathVision
CathVision is a medical technology company developing the ECGenius electrophysiology recording system and CARDIALYTICS AI suite for cardiac ablation procedures, sold to hospital electrophysiology labs and electrophysiologists treating arrhythmias.
- Company typePrivate
- Founded2013
- HeadquartersCopenhagen, Denmark
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What CathVision does
CathVision is a medical technology company founded in 2013 and headquartered in Copenhagen, Denmark, with a US commercial office in Minnetonka, Minnesota. The company develops the ECGenius System, an electrophysiology (EP) recording platform, together with the CARDIALYTICS AI software suite, targeting the cardiac electrophysiology market and specifically the workflow of catheter ablation for arrhythmias such as atrial fibrillation. Its technical foundation combines a proprietary low-noise hardware amplifier with machine-learning software modules; the company holds 13 patent families and has secured FDA 510(k) clearance for the ECGenius System (May 2022), FDA clearance for its PVI Analyzer and Signal Complexity AI algorithms (August 2023), and CE Mark (February 2025). The platform is designed to integrate with hospital EP lab infrastructure, including third-party 3D mapping systems and EMR platforms (EMR integration announced December 2024).\n\nCathVision's business model is enterprise capital equipment sales of the ECGenius recording system into hospital EP laboratories, supplemented by per-module software revenue from AI applications such as the PVI Analyzer, PFAnalyzer, Entrainment Assistant, FaST Algorithm, and CSP Assistant. Go-to-market has progressed from limited market release to commercial expansion, anchored by placements at elite US academic medical centers including Cleveland Clinic, Johns Hopkins, Houston Methodist, NYU Langone, IU Health, Valley Health, and University of Vermont, with initial European footprint at OLV Hospital Aalst in Belgium following CE Mark. The company operates with 11–50 employees, has built an R&D organization of 20+ engineers under VP Engineering Allan Gersfelt-Larsen, and has raised approximately $30M across multiple funding rounds between 2017 and 2023.
CathVision firmographics
Firmographics- Name
- CathVision
- Legal name
- CathVision ApS
- Website
- https://cathvision.com
- Company type
- Private
- Founded year
- 2013
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- CathVision is a medical technology company developing the ECGenius electrophysiology recording system and CARDIALYTICS AI suite for cardiac ablation procedures, sold to hospital electrophysiology labs and electrophysiologists treating arrhythmias.
- Ownership category
- akta.pro rank
CathVision industry classification
Industry- Product category
- Cardiac Electrophysiology Recording Systems
- NAICS
- Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
- SIC
- Electromedical & Electrotherapeutic Apparatus (3845)
- akta.pro primary industry
- Electrophysiology Mapping & Ablation Systems (HLAHAFAD)
- akta.pro secondary industries
- Electrophysiology (Heart Rhythm) (HLAKABAC), Hemodynamic Monitoring & Cardiac Diagnostics (Cath Lab, FFR/IVUS/OCT) (HLAHAFAI)
Keywords
Where CathVision is headquartered
LocationHeadquarters
- HQ city
- Copenhagen
- HQ country
- Denmark
- HQ region
- Europe
Offices2 records
Markets served
CathVision business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Marketing or Sales, Operations, Supply Chain
Revenue model
- ECGenius System Hardware: Sale of proprietary EP recording system hardware including the amplifier and software platform. FDA-cleared for commercial sale in the United States with CE Mark for European market.
- AI Algorithm Licensing (Price-per-use): CARDIALYTICS algorithms (PVI Analyzer, Signal Complexity) available to ECGenius System users on a price-per-use basis. Provides recurring usage-based revenue from existing installed base.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Usage-based | Pay-as-you-go | AI Analytics (PVI Analyzer, Signal Complexity) available as add-on modules |
Go-to-market motion2 records
Distribution channels3 records
Marketing channels5 records
CathVision product offering
Product offeringCore offering
CathVision develops and commercializes the ECGenius System, an FDA-cleared electrophysiology (EP) recording platform with a proprietary low-noise hardware amplifier that acquires high-fidelity cardiac electrograms for ablation procedures. The company also sells the CARDIALYTICS AI analytics suite, which provides automated electrogram interpretation modules (including FDA-cleared PVI Analyzer and Signal Complexity algorithms) on a price-per-use basis to existing ECGenius users for the diagnosis and treatment of complex cardiac arrhythmias.
Product overview
CathVision offers the ECGenius System as its core hardware platform—a proprietary EP recording system that acquired FDA clearance in May 2022 and CE Mark in February 2025 for high-fidelity cardiac signal acquisition. The system integrates with the CARDIALYTICS AI analytics suite, which includes FDA-cleared modules (PVI Analyzer, Signal Complexity) and investigational modules (PFAnalyzer, FaST Algorithm, Entrainment Assistant, CSP Assistant). The ECGenius hardware serves as the foundation for AI-powered electrogram analysis, with algorithms available on a price-per-use basis.
Differentiator
Problem solved
Functional benefit
Brands
- CARDIALYTICS: Suite of AI-powered analytics including PVI Analyzer, Signal Complexity, PFAnalyzer, FaST Algorithm, Entrainment Assistant, and CSP Assistant for electrophysiology procedures
- ECGenius System
- PFAnalyzer
- Signal Complexity
- PVI Analyzer
- FaST Algorithm
- Entrainment Assistant
Products and services
- ECGenius System The ECGenius System is an FDA-cleared electrophysiology (EP) recording platform featuring a proprietary hardware amplifier that acquires high-fidelity, low-noise cardiac electrograms. It includes 12-lead ECG, 128 intracardiac channels, and 4 blood pressure channels to help electrophysiologists diagnose and treat complex cardiac arrhythmias. CE Mark received February 2025 for European distribution.
- CARDIALYTICS AI Analytics Suite CARDIALYTICS is CathVision's AI-powered analytics platform comprising multiple algorithmic modules (PVI Analyzer, Signal Complexity, PFAnalyzer, FaST Algorithm, Entrainment Assistant, CSP Assistant) that integrate with the ECGenius System to provide automated electrogram analysis during cardiac ablation procedures. Modules are available to ECGenius users on a price-per-use basis.
Quantifiable outcome
- First and only EP recording system with AI algorithm to measure success of cardiac ablation (FDA cleared August 2023)
- +2 more outcomes
Companies that use CathVision
Customer profileNamed customers7 records
Segments2 records
Ideal customer profiles2 records
CathVision technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration2 records
AI capability6 records
Feature6 records
CathVision partnerships and signals
Strategic signalPartnerships
Seven partnerships are on record, tiered core and minor.
- University of Vermont Medical CentercoreFirst US clinical trial site evaluating ECGenius System safety and technical performance. Conducted comparative benchmarking of electrogram signal quality against commercial systems.
- NYU Langone HealthcoreClinical study site evaluating Signal Complexity algorithm for persistent AF treatment. 28+ patients enrolled. Dr. Larry Chinitz serves as clinical advisor and key opinion leader.
- OLV Hospital AalstcoreEuropean clinical site for persistent AF study led by Dr. Tom De Potter. Evaluating Signal Complexity algorithm for ablation therapy impact analysis.
- AZ Sint-Jan Brugge-Oostende, UZ Gent, UZ Brussels, Clinique Pasteur ToulousecoreEuropean multicenter clinical sites for PVISION study (90 patients across 4 sites in Belgium and France) evaluating PVI Analyzer algorithm for automated pulmonary vein isolation assessment.
- HeartX Cardiovascular AcceleratorminorSelected for 2025 HeartX Cardiovascular Accelerator program focused on innovative cardiovascular healthcare solutions.
- Mount SinaicoreCollaborated on Pulsed Field Ablation research with PFAnalyzer module. Study confirmed reliability of unipolar voltage thresholds for distinguishing tissue states post-PFA.
- University Hospital of SplitcoreClinical collaborator on PFAnalyzer research letter published in Heart Rhythm journal. Demonstrated clinical feasibility of electrogram analysis tool for lesion assessment in PFA.
Scale indicators9 records
Recent moves6 records
Expansion highlights6 records
CathVision competitors and assessment
Company assessmentEmerging players
- Acutus Medical: A US-based EP mapping and ablation company offering the AcQMap system with proprietary non-contact mapping. Acutus is a comparable emerging competitor targeting advanced ablation workflows similar to CathVision's high-fidelity EP positioning.
- Stereotaxis: Pioneer in robotic EP navigation; its Genesis and Niobe systems are used in complex ablation procedures alongside conventional recording and mapping. Stereotaxis overlaps with CathVision at the high-complexity end of the EP lab market.
- Volta Medical: A French AI-focused EP medtech whose VX1 software provides AI decision support for atrial fibrillation ablation. Volta is one of the closest comparables to CathVision's CARDIALYTICS AI analytics strategy and targets the same electrophysiologist users.
Direct peers
- Abbott: Through its acquisition of St. Jude Medical, Abbott offers the CardioLab EP recording system and EnSite X mapping platform, making it a direct competitor in hospital EP labs alongside CathVision's ECGenius and CARDIALYTICS offerings.
- Boston Scientific: A leading cardiovascular medtech major that competes directly with CathVision in EP recording (LabSystem Pro) and ablation, while also offering integrated mapping systems and ablation catheters. Boston Scientific is the most direct incumbent competitor and reference customer replacement target.
- Biosense Webster (Johnson & Johnson): The market-leading EP franchise within J&J, offering the CARTO 3D mapping system and a broad ablation catheter portfolio. Biosense Webster is the dominant EP ecosystem player CathVision must position against for procedure-level data and analytics.
- GE HealthCare: Provides the Mac-Lab and CardioLab hemodynamic and EP recording systems widely used in cardiac catheterization and EP labs. GE HealthCare competes head-to-head with ECGenius in EP recording and benefits from broad hospital relationships.
Broad incumbents
- Siemens Healthineers: A large incumbent in cardiac imaging, cath lab, and EP-adjacent technologies. While not a direct EP recording rival in the same narrow category, Siemens competes for hospital cardiology capex budgets and increasingly offers digital and AI features overlapping with CARDIALYTICS.
- Philips: A broad incumbent in cardiac care including EP lab integration, imaging, and patient monitoring. While Philips does not focus specifically on standalone EP recording, it competes for hospital cardiology budgets and has historically offered EP-adjacent capital equipment.
Regional players
- MicroPort Scientific (Cardiac Rhythm Management / EP): A global medical device group with growing EP and cardiac ablation offerings, particularly strong in Asia and Europe. MicroPort is a comparable competitor in EP equipment commercialization, though its primary geographic strengths differ from CathVision's US-anchored base.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
CathVision social profiles
Digital presenceCathVision compliance and trust
Trust signalCompliance3 records
CathVision financial estimates
Financial estimateRevenue estimate
Valuation estimate
CathVision leadership team
Management profileNumber of profiles
Profiles9 records
CathVision funding detail
Funding detailFunding overview
Funding rounds8 records
Investors6 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
CathVision M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about CathVision
What does CathVision do?
CathVision develops and commercializes the ECGenius System, an FDA-cleared electrophysiology (EP) recording platform with a proprietary low-noise hardware amplifier that acquires high-fidelity cardiac electrograms for ablation procedures. The company also sells the CARDIALYTICS AI analytics suite, which provides automated electrogram interpretation modules (including FDA-cleared PVI Analyzer and Signal Complexity algorithms) on a price-per-use basis to existing ECGenius users for the diagnosis and treatment of complex cardiac arrhythmias.
Is CathVision a public or private company?
CathVision is a private company. It is classified as venture growth investor backed and is currently operating.
When was CathVision founded?
CathVision was founded in 2013. It employs 11 to 50 people.
Where is CathVision based?
CathVision is headquartered in Copenhagen, Denmark, in the Europe region.
How does CathVision make money?
Two revenue lines are on record. ECGenius System Hardware is the primary driver. The others are AI Algorithm Licensing (Price-per-use).
Who are CathVision's main competitors?
Emerging players on record are Acutus Medical, Stereotaxis and Volta Medical. Direct peers are Abbott, Boston Scientific, Biosense Webster (Johnson & Johnson) and GE HealthCare. Broad incumbents are Siemens Healthineers and Philips. MicroPort Scientific (Cardiac Rhythm Management / EP) is listed as a regional player.
Does CathVision have an API?
No public API is recorded for CathVision.
What industry is CathVision in?
CathVision's product category is Cardiac Electrophysiology Recording Systems. Its primary akta.pro industry code is HLAHAFAD, Electrophysiology Mapping & Ablation Systems, with a secondary code of HLAKABAC, Electrophysiology (Heart Rhythm). Its NAICS code is 334510 and its SIC code is 3845.